Literature DB >> 7679034

Identification of a novel calcium antagonist binding site in rat brain by SR 33557.

B A Kenny1, S Fraser, M Spedding.   

Abstract

1. In K(+)-depolarized taenia preparations from guinea-pig caecum SR 33557 was a potent antagonist of Ca(2+)-induced contractions and antagonized the effect of the calcium channel activator Bay K 8644. 2. SR 33557 displayed high affinity (pKi 9.54 +/- 0.04, nH 1.01) for the [3H]-(+/-)-PN 200-110 binding site in rat cerebral cortex membranes. In the presence of 5 mM Ca2+ this affinity was reduced (pKi 8.82 +/- 0.01, nH 1.05) whilst the affinity of nitrendipine was unaffected by this concentration of Ca2+. 3. Saturation binding experiments in rat cerebral cortex carried out in the absence and presence of SR 33557 (0.1-1.0 nM) indicated an apparently competitive interaction at the dihydropyridine site, in that SR 33557 reduced the KD of [3H]-(+/-)-PN 200-110 binding without any effect on Bmax. In kinetic experiments, the rate of dissociation of [3H]-(+/-)-PN 200-110 from rat cerebral cortex was unchanged in the presence of SR 33557 (5 nM). 4. D-cis-diltiazem fully reversed the inhibition [3H]-nitrendipine binding to rat cerebral cortex produced by SR 33557 indicating the site of action of SR 33557 to be distinct from the dihydropyridine (DHP) binding site. 5. Saturation analysis indicated that [3H]-SR 33557 (0.01-0.8 nM) labelled a single class of binding sites in rat cerebral cortex membranes with high affinity (KD 0.12 +/- 0.01, Bmax 222 +/- 20 fmol mg-1 protein), although kinetic data indicated the existence of negative cooperativity between the binding sites. 6.In competition studies, a variety of different calcium antagonists displayed similar affinity for [3H]-SR 33557 and [3H]-(+/-)-PN 200-110 sites. The [3H]-SR 33557 site was sensitive to the inhibitory effect of divalent cations. The affinity of Cd2+ was 0.026 +/- 0.015 mM and the rank order of affinity was Cd2+ >Ca2+ >Mn2+ >Mg2+ >Na+.7. We propose that SR 33557 labels a distinct site in rat cerebral cortex. The coupling between the SR 33557 and DHP site appears to be very close, resulting in apparently competitive interactions in some experimental protocols but can be revealed as negatively allosteric in other circumstances.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679034      PMCID: PMC1907724          DOI: 10.1111/j.1476-5381.1993.tb13445.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

Review 1.  Voltage-dependent calcium channels: structures and drug-binding sites.

Authors:  M Spedding; B Kenny
Journal:  Biochem Soc Trans       Date:  1992-02       Impact factor: 5.407

2.  Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters.

Authors:  J M VAN ROSSUM
Journal:  Arch Int Pharmacodyn Ther       Date:  1963

Review 3.  Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes.

Authors:  R P Mason; D G Rhodes; L G Herbette
Journal:  J Med Chem       Date:  1991-03       Impact factor: 7.446

4.  Selective antagonism of calcium channel activators by fluspirilene.

Authors:  B A Kenny; S Fraser; A T Kilpatrick; M Spedding
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

5.  Substituted diphenylbutylpiperidines bind to a unique high affinity site on the L-type calcium channel. Evidence for a fourth site in the cardiac calcium entry blocker receptor complex.

Authors:  V F King; M L Garcia; J L Shevell; R S Slaughter; G J Kaczorowski
Journal:  J Biol Chem       Date:  1989-04-05       Impact factor: 5.157

6.  Amiloride analogs inhibit L-type calcium channels and display calcium entry blocker activity.

Authors:  M L Garcia; V F King; J L Shevell; R S Slaughter; G Suarez-Kurtz; R J Winquist; G J Kaczorowski
Journal:  J Biol Chem       Date:  1990-03-05       Impact factor: 5.157

7.  SR33557, an indolizinsulfone blocker of Ca2+ channels: identification of receptor sites and analysis of its mode of action.

Authors:  A Schmid; G Romey; J Barhanin; M Lazdunski
Journal:  Mol Pharmacol       Date:  1989-06       Impact factor: 4.436

8.  SR 33557, a novel calcium-antagonist: interaction with [3H]-(+/-)-nitrendipine and [3H]-(-)-desmethoxy-verapamil binding sites in cerebral membranes.

Authors:  P Nokin; M Clinet; P Polster; P Beaufort; L Meysmans; J Gougat; P Chatelain
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989 Jan-Feb       Impact factor: 3.000

9.  Characterization of the slow calcium channel binding sites for [3H]SR 33557 in rat heart sarcolemmal membranes.

Authors:  P Chatelain; P Beaufort; L Meysmans; M Clinet
Journal:  Mol Pharmacol       Date:  1991-01       Impact factor: 4.436

10.  Interaction of SR 33557 with skeletal muscle calcium channel blocker receptors in the baboon: characterization of its binding sites.

Authors:  J Sol-Rolland; M Joseph; M Rinaldi-Carmona
Journal:  J Pharmacol Exp Ther       Date:  1991-05       Impact factor: 4.030

View more
  2 in total

1.  Inhibitory action of SR33557 on L-type calcium current in single ventricular myocytes of rat.

Authors:  K Yasui; P Palade
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

Review 2.  Molecular pharmacology of high voltage-activated calcium channels.

Authors:  Clinton J Doering; Gerald W Zamponi
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.